Asahi Kasei Pharma has entered an exclusive global license agreement with Alchemedicine, a company specializing in the discovery of small molecule drugs, covering novel lead compounds for a single target. Under the agreement, Asahi Kasei Pharma obtains exclusive worldwide rights to research, develop, manufacture, and commercialize the compounds, which are currently at the preclinical stage. The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP and are expected to ...